Author

N. Mentens

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

D. Dierickx· 2 shared J. Cools· 2 shared K. Jacobs· 2 shared M. Vanden Bempt· 2 shared N. Meeuws· 2 shared O. Gielen· 2 shared S. Demeyer· 2 shared A. Veloso· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Dierickx

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dual targeting of EZH2 and Histone Deacetylases in hematological malignancies promotes transcriptional and metabolic deregulation leading to ferroptosis

A. Veloso, T. Slegers, J. Schoenaker, S. Demeyer, S. Van den Bergh, M. Aertgeerts, K. Verhoeft, Y. Schoenmaekers, N. Meeuws, I. Bischops, F. Renard, L. Boogaerts, N. Mentens, O. Gielen, K. Jacobs, , M. Vanden Bempt

This study shows that targeting EZH2 and HDACs together induces ferroptosis in hematological malignancies by upregulating cholesterol biosynthesis and causing metabolic stress.

bioRxiv · Mar 3, 2024 · PreprintCancer Biology

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma

M. Vanden Bempt, K. Debackere, S. Demeyer, Q. Van Thillo, N. Meeuws, S. Provost, N. Mentens, K. Jacobs, O. Gielen, D. Nittner, S. Ogawa, K. Kataoka, C. Graux, T. Tousseyn, J. Cools, D. Dierickx

The paper identifies MYCN overexpression in PTCL and shows EZH2 as a transcriptional co-factor for MYCN-driven gene activation, with therapeutic implications for HDAC inhibitors.

bioRxiv · Mar 31, 2022Cancer Biology